Posts by: Alejandra Viviescas, PhD

News

Mutations in the NUDT15 gene may predict predisposition to side effects of immunosuppressants — substances that change the function of the immune system — in European patients with inflammatory bowel disease (IBD), ... Read more

February 25, 2019February 25, 2019

Humira Safe and Effective for up to Six Years in Crohn’s Disease Patients, Study Shows

News

Humira (adalimumab) is safe and effective for Crohn’s disease (CD) patients for up to six years when used in routine clinical practice, a study suggests. The study, “Adalimumab Effectiveness Up ... Read more

February 22, 2019February 22, 2019

FDA Accepts Koutif Therapeutics’ Investigational New Drug Application for KT-1002

News

The U.S. Food and Drug Administration (FDA) has accepted Koutif Therapeutics’ investigational new drug (IND) application for KT-1002. The company is set to begin a Phase 1 clinical trial testing the experimental therapy in inflammatory ... Read more

February 8, 2019February 8, 2019

Diet Rich in Fish-derived Fats Might Cut IBD Risk, Review Study Suggests

News

A diet rich in fish, especially those containing high amounts of long-chain polyunsaturated fatty acids (PUFAs), might reduce the risk of inflammatory bowel disease, a review study suggests. But further studies are ... Read more

January 23, 2019January 23, 2019

Gut Microbe-Derived Molecule UroA and Its Artificial Version Show Promise for IBD

News

Urolithin A (UroA), a molecule produced by gut microbes, and its made-in-the-lab version, UAS03, alleviated and prevented symptoms of inflammatory bowel disease (IBD) in a cell and animal study. ... Read more

January 16, 2019January 16, 2019

Oral Treatment Candidate Etrasimod Found to be Safe and Effective for Ulcerative Colitis, Open-label Trial Extension Shows

News

Arena Pharmaceuticals announced that its investigational oral treatment, Etrasimod, led to long-term clinical response and remission in patients with ulcerative colitis. The candidate treatment was also found to be safe ... Read more

January 4, 2019January 4, 2019

Abivax to Present Results of Trials of ABX464 as Ulcerative Colitis Therapy

News

Abivax will present the complete results of its Phase 2a trial ABX464-101 (NCT03093259) and interim results of the open-label extension study ABX464-102 (NCT03368118). Both aimed to assess the safety and efficacy of ABX464 as a ... Read more

December 14, 2018December 14, 2018

Janssen Launching Phase 1 Trial Testing VE202 for Potential IBD Treatment

News

Janssen Biotech will conduct a Phase 1 clinical trial in healthy volunteers to test VE202, an investigational oral treatment for inflammatory bowel disease (IBD), Vedanta Biosciences has announced. In 2015, Janssen ... Read more

Posts by: Alejandra Viviescas, PhD

Alejandra Viviescas, PhD

Gene Mutations May Predict Risk of IBD Treatments’ Side Effects

Humira Safe and Effective for up to Six Years in Crohn’s Disease Patients, Study Shows

FDA Accepts Koutif Therapeutics’ Investigational New Drug Application for KT-1002

Diet Rich in Fish-derived Fats Might Cut IBD Risk, Review Study Suggests

Gut Microbe-Derived Molecule UroA and Its Artificial Version Show Promise for IBD

Oral Treatment Candidate Etrasimod Found to be Safe and Effective for Ulcerative Colitis, Open-label Trial Extension Shows

Abivax to Present Results of Trials of ABX464 as Ulcerative Colitis Therapy

Janssen Launching Phase 1 Trial Testing VE202 for Potential IBD Treatment

Pin It on Pinterest